582,416 Shares in Boston Scientific Corporation $BSX Purchased by Nykredit A S

Posted by Geri Gentry on Sep 4th, 2026

Boston Scientific logo Nykredit A S bought a new position in Boston Scientific Corporation (NYSE:BSX – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 582,416 shares of the medical equipment provider’s stock, valued at approximately $24,858,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. B. Metzler seel. Sohn & Co. AG lifted its position in Boston Scientific by 25.8% during the second quarter. B. Metzler seel. Sohn & Co. AG now owns 333,583 shares of the medical equipment provider’s stock valued at $14,237,000 after purchasing an additional 68,450 shares during the period. Natural Investments LLC grew its position in Boston Scientific by 1.3% in the 2nd quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after purchasing an additional 206 shares during the period. Legacy Financial Advisors Inc. grew its position in Boston Scientific by 91.0% in the 2nd quarter. Legacy Financial Advisors Inc. now owns 11,942 shares of the medical equipment provider’s stock worth $510,000 after purchasing an additional 5,691 shares during the period. Proficio Capital Partners LLC purchased a new stake in Boston Scientific during the 2nd quarter valued at $434,000. Finally, Teza Capital Management LLC raised its stake in Boston Scientific by 21.1% during the 2nd quarter. Teza Capital Management LLC now owns 6,258 shares of the medical equipment provider’s stock valued at $267,000 after buying an additional 1,089 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 3.0%

NYSE BSX opened at $46.93 on Friday. The stock’s 50-day moving average price is $46.83 and its 200-day moving average price is $55.79. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50. The company has a market capitalization of $68.01 billion, a P/E ratio of 19.00, a price-to-earnings-growth ratio of 1.12 and a beta of 0.57.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has initiated a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other news, Director David C. Habiger bought 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BSX shares. Robert W. Baird set a $56.00 price target on Boston Scientific in a research note on Thursday, July 30th. Evercore set a $65.00 price objective on Boston Scientific in a research report on Monday, July 6th. Jefferies Financial Group lowered their target price on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, June 24th. UBS Group dropped their target price on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 price target on Boston Scientific in a research note on Wednesday, July 29th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Get Our Latest Stock Report on BSX

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.